Analyst Ratings for Seelos Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, Seelos Therapeutics (NASDAQ:SEEL) received 2 bullish and 2 somewhat bullish analyst ratings. The average 12-month price target for the stock is $5.25, a 12.5% decrease from the previous average of $6.00.
June 23, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Seelos Therapeutics received positive analyst ratings, with an average 12-month price target of $5.25, down 12.5% from the previous average.
Seelos Therapeutics received a majority of positive analyst ratings in the last quarter, indicating a positive outlook for the stock. However, the average 12-month price target has decreased by 12.5%, which may suggest a more cautious view on the stock's potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100